Metabolic Syndrome: From Target Molecules to Therapeutic Approaches

Dear Colleagues,

Metabolic syndrome is a widespread medical condition characterized by a cluster of health issues that increase the risk of cardiovascular disease and type 2 diabetes mellitus. Common risk factors associated with metabolic syndrome include abdominal obesity, high blood sugar, hypertension, elevated triglyceride levels and low levels of high-density lipoprotein cholesterol. Diagnosis of metabolic syndrome requires the presence of at least three of these five metabolic abnormalities simultaneously, as proposed by major organizations involved in its study. Additional factors, such as chronic inflammation and blood clotting, have also been implicated in metabolic syndrome, highlighting its complex nature. While lifestyle changes are effective in the early stages of the condition, pharmacological treatments are often needed in advanced cases. Currently, pharmacological interventions target the individual components of metabolic syndrome separately, although new drugs are being studied. Furthermore, although the dysfunction of adipose tissue is recognized as a major contributor to metabolic dysregulation, it remains an area of limited research. The development of metabolic syndrome is influenced by the interactions between human microbiota, genetic factors and diet. Precision medicine based on an understanding of the molecular landscape of metabolic syndrome has emerged as a promising approach. Given the increasing prevalence of metabolic syndrome globally and the limited understanding of its underlying mechanisms, there is a need to explore the biological pathways involved in this condition and develop more effective treatment strategies.

The aim of this research topic is to provide new insights into metabolic pathways or molecular targets that could aid in understanding and treating metabolic syndrome and its complications. Understanding the pathways involved in metabolic dysregulation is crucial for developing interventions. Additionally, we are interested in studies that provide evidence on different treatment modalities for metabolic syndrome, including nutritional interventions, bariatric surgery, modulation of gut microbiota, anti-inflammatory drugs and pharmacological treatments that can improve metabolic dysfunction.

Dr. Silvia Paredes
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• metabolic syndrome
• hypertension
• dyslipidemia
• glucose intolerance
• adipose tissue
• adypocite dysfunction
• oxidative stresse
• endothelial cell dysfunction
• inflammation
• bile acid signaling pathway
• gut microbiota